secwatch.observer — SEC 8-K summary
======================================

Issuer:     Greenland Mines Ltd (GRML)
CIK:        0001907223
Form:       8-K
Filed at:   2025-07-22T23:59:59+00:00
Accession:  0001213900-25-066676
Event type: m_and_a
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Klotho Neurosciences enters exclusive global gene therapy license with AAVnerGene
--------------------------------------------------------------------------------

- Exclusive global rights to AAVnerGene's AAVone platform for three gene therapy programs: KLTO-101, KLTO-202, KLTO-303.
- Initial license fees: $250,000 (first product) to $500,000 (third product); plus 2% royalty on revenue.
- Targets Alzheimer's, Parkinson's, ALS, motor neuron diseases, and aging-related pathologies.
- CEO cites faster, cheaper manufacturing with higher purity and lower toxicity via AAVone and ATHENA platforms.
- Partnership aims to accelerate clinical development and reduce high drug price/dose-related toxicity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1907223/000121390025066676/0001213900-25-066676-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1907223/000121390025066676/ea0249890-8k_klotho.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-066676

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer